Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 53 of 1,261
  1. US 12258627

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  2. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Nanjing Legend Biotech Co., Ltd Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  3. US 12258367

    Glucoside derivative that acts as SGLT1 inhibitor and application thereof

    Medshine Discovery Inc. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  4. US 12258341

    IRAK degraders and uses thereof

    Kymera Therapeutics, Inc. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  5. US 12258370

    Betulastatin compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  6. US 12258372

    Recombinant vaccine against Marek's disease and Newcastle disease

    The United States of America, as represented by the Secretary of Agriculture Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  7. US 12258401

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  8. US 12258412

    Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

    REGENERON PHARMACEUTICALS, INC. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  9. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  10. US 12257311

    Multimeric T-cell modulatory polypeptides and methods of use thereof

    Cue Biopharma, Inc. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  11. US 12259378

    Dynamic clamps and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  12. US 12258354

    AhR modulators

    IDEAYA Biosciences, Inc. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  13. US 12257288

    Methods of inducing immune tolerance to clotting factors

    BIOVERATIV THERAPEUTICS INC. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  14. US 12257325

    Chelating platform for delivery of radionuclides

    The Regents of the University of California Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  15. US 12258316

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  16. US 12257224

    Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

    Milestone Pharmaceuticals Inc. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  17. US 12257247

    Targeted degradation of VAV1

    Monte Rosa Therapeutics AG Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  18. US 12257242

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  19. US 12257132

    Hydrogen-delivering system for a bodily orifice

    H2 Universe LLC Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  20. US 12257277

    Adeno-associated virus formulations

    Takeda Pharmaceutical Company Limited Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  21. US 12257262

    Method of reconstituting liposomal annamycin

    The Board of Regents of the University of Texas System Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  22. US 12257235

    Methods and materials for using ruminococcus gnavus or clostridium sporogenes to treat gastrointestinal disorders

    The Regents of the University of California Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  23. US 12257261

    Preparation of preliposomal Annamycin lyophilizate

    The Board of Regents of the University of Texas System Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted
  24. US 12257326

    TCO conjugates and methods for delivery of therapeutic agents

    The Regents of the University of California Β· Granted Mar 25, 2025 Β· Expires Mar 20, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.